Search company, investor...
CB2 Insights company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


About CB2 Insights

CB2 Insights develops information technology (IT) solutions for the healthcare industry to maximize productivity, improve clinical workflow, and offer patient care and management. The company develops Sail Cannabis, a solution which brings medical cannabis as an alternative therapy. It offers patient care management, enhanced preparation procedures, electronic medical document transmission and verification, reporting tools and auditing measures, and monitoring tools and follow-up procedures.

CB2 Insights Headquarters Location

5045 Orbitor Drive Building 11, Suite 300

Mississauga, Ontario, L4W 4Y4,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CB2 Insights

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CB2 Insights is included in 2 Expert Collections, including Cannabis.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.


Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

CB2 Insights Patents

CB2 Insights has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Capacitors, Analog circuits, Electronic design, Oscillators, Linear filters


Application Date


Grant Date



Related Topics

Capacitors, Analog circuits, Electronic design, Oscillators, Linear filters



Latest CB2 Insights News

Skylight Health Group upgraded at Research Capital

Jan 5, 2022

Skylight Health Group upgraded at Research Capital Research Capital analyst Yue (Toby) Ma has upgraded Skylight Health Group ( Skylight Health Group Stock Quote, Chart, News, Analysts, Financials TSXV:SLHG ) from “Hold” to “Speculative Buy” in an update to clients on Monday, saying investors should take advantage of the stock’s favourable risk/reward position. Along with the new rating, Ma reduced his target price on SLHG from $4.80/share to $3.20/share for a projected return at the time of publication of 94 per cent. Founded as CB2 Insights Inc. in 2014 and headquartered in Mississauga, Skylight Health Group is a healthcare services and technology company, operating a multi-state primary care network throughout the United States, a proprietary electronic health record system and a subscription-based telemedicine service for the un/under-insured population. Having previously downgraded the stock on September 17, Ma’s updated rating and target come with a belief that Skylight is in an attractive position in the middle of a transition phase, though the lower price is on account of overall industry performance. “We are using a lower multiple as valuations of both primary care and Canadian healthcare services sectors continue being weak,” Ma said. Skylight’s business focus has been on shifting toward a value-based care model, having partnered with a leading national healthcare organization who is a recipient of a Direct Contracting Entity license in October, with participation effective as of January 1, one of two value-based care programs Skylight participates in. All told, Skylight has a roster of nearly 100,000 primary care lives – among which 13,000 are considered Medicare and Medicare equivalent lives, meaning they are either traditional Medicare patients or patients eligible for Medicare Advantage, Medicaid and/or other value-based care arrangements. The company has been working toward bringing some extra cash into the fold, having closed on December 7 on the raise of US$5.8 million through the issuance of 275,000 shares of 9.25 per cent Series A redeemable preferred shares at a price of US$21/share. The end of 2021 also saw Skylight complete its divestiture of its legacy business and Canna Care Docs to New Frontier Docs for total cash considerations of US$8.63 million, further cementing the company’s shift toward value-based care. In total, $4 million in cash was due at closing, with the remainder to be paid out after 12, 18, and 24 months. “We remain proud of the work we achieved together as a team in building the legacy business; this move forward is critical towards building our primary and value-based care business in the United States,” said Prad Sekar, Skylight’s Chief Executive Officer in the company’s December 15 press release. “Fee-for-service (FFS) primary care providers are facing enormous challenges in terms of increased costs and competition while concurrently trying to navigate a move towards value-based care. Skylight Health Group is well positioned to support, navigate, and lead alongside physician-owned primary care practises toward a radically changing primary care market.” Management previously noted it would use the proceeds from the two transactions to acquire additional independent primary care practises in existing markets to increase the company’s market density, according to Ma. Looking forward, Ma projects slight revenue growth for Skylight in his financial analysis, beginning with a spike to a projected $50.5 million in revenue for 2022 for a potential year-over-year increase of 26.4 per cent, then levelling out to minimal growth rates through 2025, projecting $51.5 million in 2023 (two per cent year-over-year increase), $52 million in 2024, and $52.5 million in 2025. Accordingly, Ma projects a relatively stable P/Sales multiple for the same time period, dropping from 1.8x in 2021 to a projected 1.4x in 2022, remaining there through 2023 and 2024 before dipping to a projected 1.3x in 2025. Ma noted that the current revenue models do not make any assumptions of value-based care revenues as Research Capital awaits management’s guidance. Meanwhile, Ma also projects the company’s adjusted EBITDA losses to drop moving forward, projecting a shift from a $7.9 million loss in 2021 to a forecasted $3 million loss in 2022, then dropping to a projected $2.7 million annual loss from 2023 through 2025. As Skylight continues its shift from fee-for-service to value-based care, Ma poses a number of questions for investors to consider. “(i) How are those 13,000 patients distributed into traditional Medicare, Medicare Advantage, commercial and Medicaid? (ii) How many of those 13,000 patients can be enrolled to the MSSP and DC programs, respectively? (iii) How fast can they be enrolled? (iv) How would revenues from the two VBC programs be recognized on SLHG’s income statement? (v) What is the per patient revenue like under the DC program? (vi) What are potential pushbacks from patients while converting them from FFS to VBC? (vii) What are potential challenges SLHG could face in operations while converting patients from FFS to VBC?” Ma wrote. Skylight’s stock price has dropped by 72.1 per cent over the last year, with a 52-week high of $9.25/share coming on February 18, before gradually dropping off to its present value of $1.63/share, which is a 52-week low.

CB2 Insights Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CB2 Insights Rank

  • When was CB2 Insights founded?

    CB2 Insights was founded in 2014.

  • Where is CB2 Insights's headquarters?

    CB2 Insights's headquarters is located at 5045 Orbitor Drive, Mississauga.

  • What is CB2 Insights's latest funding round?

    CB2 Insights's latest funding round is Reverse Merger.

  • How much did CB2 Insights raise?

    CB2 Insights raised a total of $4.06M.

  • Who are the investors of CB2 Insights?

    Investors of CB2 Insights include 10557404 Canada Corp, Plant-Based Investment Corp. and Merida Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.